Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TN-1111
- Development stage
- Preclinical
- Lead developer
- TransGenex Nanobiotech
01
Overview
TN-1111 is a preclinical-stage therapeutic candidate developed by TransGenex Nanobiotech that targets cancer stem cells (CSCs). Identified through the company's proprietary Functional in-vivo Stem cell Screening (FiSS) platform, TN-1111 is designed to inhibit signaling pathways that regulate the interactions between tumor and stromal cells. These pathways are essential for the maintenance of CSCs, which are often resistant to standard chemotherapy and radiation, contributing to tumor recurrence and metastasis. While the specific molecular targets and modality of TN-1111 have not been disclosed, it is being developed as a targeted therapy to eliminate the stem cell population within tumors.
Beyond the preview
Go deeper on TN-1111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TN-1111.